6505--Allopurinol Tablets

The Department of Veterans Affairs National Acquisition Center is soliciting proposals for Allopurinol Tablets through Solicitation Number 36E79725R0067, a pharmaceutical prime vendor contract serving multiple federal agencies including the VA, Department of Defense, Bureau of Prisons, and Indian Health Service. The solicitation covers five line items of Allopurinol tablets in 100mg and 300mg strengths across various package sizes (100, 500, and 1,000 tablet bottles), with estimated annual usage ranging from 3,809 to 160,690 bottles depending on the package configuration and agency. Prospective contractors must meet FDA current Good Manufacturing Practices (cGMP) requirements, provide unique National Drug Code (NDC) numbers, and submit a Letter of Commitment from the manufacturer. All offerors must submit pricing for all line items and option years, including a mandatory 0.5% Cost Recovery Fee. The revised proposal due date is December 2, 2025, at 2:30 PM Central Time, as extended from the original November 24, 2025 deadline.

This is an unrestricted solicitation with no set-aside designation, though it applies a small business size standard of 1,300 employees. The contract will be structured as a five-year requirements contract consisting of a base year plus four one-year option periods, with one aggregate award anticipated for all line items across the entire contract period. No specific budget range or award value is disclosed in the solicitation documents. The contract will serve multiple federal agencies with varying usage requirements, reflecting the multi-agency nature of this pharmaceutical procurement. Place of performance is not specified as a limiting factor, though the solicitation is administered by the VA's OPAL/National Acquisition Center located in Hines, Illinois.